THERAPY DOSSIER · th-27f2ffde281d

Human embryonic stem cell-derived hepatocyte-like cells and their secreted proteins (secretome)

Biologic · Cell therapy (embryonic stem cell-derived hepatocyte-like cells + secretome), preclinical; no matching trial identified

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: Cell therapy (embryonic stem cell-derived hepatocyte-like cells + secretome), preclinical; no matching trial identified
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22138358 ↗2011Reported benefit

Direct and indirect contribution of human embryonic stem cell-derived hepatocyte-like cells to liver repair in mice.

MouseChemical/toxinBALB/c and nude miceIntrasplenic injection for cells; intraperitoneal injection for secreted proteinsAfter carbon tetrachloride-induced injury

Model: Carbon tetrachloride-induced acute liver injury

Hepatocyte-like cells showed features of normal hepatocytes, engrafted efficiently and retained hepatic characteristics, promoted host hepatocyte proliferation and revascularisation of injured liver. Injection of the secreted proteins alone produced significant tissue regeneration without cell graf…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…